Clinical Trial Update: Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients

View source ↗

Summary

A clinical trial evaluating SANGUINATE for sickle cell disease has been withdrawn. The document summarizes safety and pharmacokinetics considerations in SCD pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• SANGUINATE

Snippet

Sponsor: Prolong Pharmaceuticals | Conditions: Sickle Cell Disease | Status: WITHDRAWN